Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results of Phase I clinical studies for two of its pipeline candidates at the 2023 European Society for Medical Oncology (ESMO) Congress. The spotlight will be on ABSK011, a small-molecule FGFR4 inhibitor, and ABSK043, an in-house developed oral programmed-death ligand 1 (PD-L1) inhibitor, showcasing Abbisko’s commitment to advancing innovative cancer treatments.
ABSK011: Targeting Hepatocellular Carcinoma
The Phase I clinical data for ABSK011 indicates good overall safety and tolerability in the treatment of hepatocellular carcinoma (HCC) patients. Notably, the ABSK011 BID cohort demonstrated exceptional efficacy in HCC patients with FGF19 overexpression, achieving an objective response rate (ORR) of up to 40.7%. These findings underscore the potential of ABSK011 as a potent treatment option for HCC, a prevalent form of liver cancer.
ABSK043: Advancing Solid Tumor Treatments
At ESMO 2023, Abbisko will also release the first preliminary results from the dosage escalation stage of the first-in-human study for ABSK043 in patients with advanced solid tumors. ABSK043 has reached a 1000mg BID dosage and is currently well tolerated, with no dose-limiting toxicity events reported. Its safety profile aligns with that of monoclonal antibody immune checkpoint inhibitors, and preliminary anti-tumor activity has been observed, signaling a promising future for this oral PD-L1 inhibitor in oncology.-Fineline Info & Tech
